However, it is important to mention that the tumour was platinum resistant and did not harbour gBRCAm (or mutations in other DDR genes) [35], which could be the main reason driving olaparib resistance in this case, regardless of PARP1 status. The gene discussed is PARP1; the disease is neoplasm.